Omeros (OMER) Research & Development (2010 - 2026)
Omeros (OMER) posted Research & Development of $13.4 million for Q1 2026, down 31.31% sequentially from $19.4 million in Q4 2025, and down 43.98% YoY from $23.8 million in Q1 2025.
Omeros (OMER) Research & Development (2010 - 2026) Analysis & Trends
Omeros has reported Research & Development for 17 years, with the latest figure at $13.4 million in Q1 2026.
- Quarterly Research & Development fell 43.98% year-over-year to $13.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $70.8 million (down 39.27% YoY) and the FY2025 annual result came in at $81.3 million, down 31.98% from the prior year.
- Research & Development slipped to $13.4 million in Q1 2026 per OMER's latest filing, from $19.4 million in the prior quarter.
- Over five years, Research & Development peaked at $45.3 million in Q2 2024 and troughed at $13.4 million in Q1 2026.
- A 5-year average of $26.0 million and a median of $24.1 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development surged 53.0% in 2024, then slumped 51.47% in 2025.
- Over 5 years, Research & Development stood at $26.5 million in 2022, then advanced by 8.82% to $28.9 million in 2023, then retreated by 19.28% to $23.3 million in 2024, then retreated by 16.61% to $19.4 million in 2025, then sank by 31.31% to $13.4 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $13.4 million, $19.4 million, and $16.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 13.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.80 Mn |
| Mar 31, 2026 | 13.36 Mn |
| Dec 31, 2025 | 19.45 Mn |
| Sep 30, 2025 | 16.00 Mn |
| Jun 30, 2025 | 22.01 Mn |
| Mar 31, 2025 | 23.85 Mn |
| Dec 31, 2024 | 23.32 Mn |
| Sep 30, 2024 | 24.08 Mn |
| Jun 30, 2024 | 45.35 Mn |
| Mar 31, 2024 | 26.77 Mn |
| Dec 31, 2023 | 28.89 Mn |
| Sep 30, 2023 | 31.73 Mn |
| Jun 30, 2023 | 29.64 Mn |
| Mar 31, 2023 | 24.61 Mn |
| Dec 31, 2022 | 26.55 Mn |
| Sep 30, 2022 | 38.57 Mn |
| Jun 30, 2022 | 23.52 Mn |
| Mar 31, 2022 | 24.09 Mn |
| Dec 31, 2021 | 30.33 Mn |
| Sep 30, 2021 | 25.82 Mn |